LONDON: Scancell Holdings plc (AIM: SCLP), a developer of cancer immunotherapies, has appointed Dr. Phil L’Huillier as the new Chief Executive Officer, effective November 18, 2024.
Dr. L’Huillier, previously CEO of CatalYm GmbH, brings extensive experience in expanding investor bases and progressing clinical studies. Professor Lindy Durrant, the current CEO, will remain in her role until Dr. L’Huillier takes over and will continue as Chief Scientific Officer.
Scancell’s Chairman, Dr. Jean-Michel Cosséry, praised Dr. L’Huillier’s track record in cancer therapeutics and welcomed his leadership.
Dr. L’Huillier expressed excitement about joining Scancell at a pivotal time, highlighting the potential of the company’s cancer vaccine platforms, ImmunoBody® and Moditope®.
Professor Durrant reflected on her tenure, noting the progress of clinical trials and the promising future for Scancell as it transitions to a late-stage clinical company. She looks forward to supporting Dr. L’Huillier and continuing her work as CSO.
Scancell initiates development of novel DNA vaccine against COVID-19